The drug Relyvrio was approved by the U.S. Food and Drug Administration on Thursday, making it the third ALS treatment to get the regulator's nod after Japanese firm Mitsubishi Tanabe's Radicava, priced at around $170,000 per year, and the generic drug riluzole. As Australia calls end to COVID emergency response, doctors warn of risk to public Australia will end the mandatory five-day home quarantine for COVID-infected people on Oct. 14, Prime Minister Anthony Albanese said on Friday, even as some doctors warned the move would put the public at risk.